Citation Impact
Citing Papers
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
2008 Standout
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
2008 Standout
Epidermal Growth Factor Receptor Variant III Status Defines Clinically Distinct Subtypes of Glioblastoma
2007
An Open-Label, Randomized Study Comparing Efficacy and Safety of Intravenous Piperacillin/Tazobactam and Ampicillin/Sulbactam for Infected Diabetic Foot Ulcers
2005
Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase
2004
Herceptin: mechanisms of action and resistance
2005
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
2008 Standout
Antitumor activity of HER-2 inhibitors
2004
Strategies to target HER2/neu overexpression for cancer therapy
2003
Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors
2011
The DNA-damage response in human biology and disease
2009 StandoutNature
EGFR Antagonists in Cancer Treatment
2008 Standout
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
2013 StandoutNature
Integrins in cancer: biological implications and therapeutic opportunities
2009 Standout
Factors associated with treatment failure in patients with diabetic foot infections: An analysis of data from randomized controlled trials
2008
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
2009 StandoutNature
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
2007 Standout
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
2006
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
Malignant astrocytic glioma: genetics, biology, and paths to treatment
2007 Standout
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
2011 Standout
Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers
2008 Standout
Wound Healing Dressings and Drug Delivery Systems: A Review
2007 Standout
Epidermal growth factor receptor family tyrosine kinases as signal integrators and therapeutic targets
2003
Targeting cancer with small molecule kinase inhibitors
2008 Standout
Drug discovery for a new generation of covalent drugs
2012
Malignant Gliomas in Adults
2008 Standout
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers
2005 Standout
Classification of anticancer drugs—a new system based on therapeutic targets
2003
Cancer immunotherapy comes of age
2011 StandoutNature
Diagnostics and treatment of the diabetic foot
2012
Cisplatin: The first metal based anticancer drug
2019 Standout
β-Arrestin–mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection
2007 StandoutNobel
Comprehensive analysis of kinase inhibitor selectivity
2011 Standout
Integration of EGFR inhibitors with radiochemotherapy
2006
Diabetic foot infection: a critical review of recent randomized clinical trials on antibiotic therapy
2011
Antimicrobial strategies centered around reactive oxygen species – bactericidal antibiotics, photodynamic therapy, and beyond
2013 Standout
Anti‐cancer properties of anthraquinones from rhubarb
2006 Standout
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
2009 Standout
Ertapenem Once Daily Versus Piperacillin‐Tazobactam 4 Times per Day for Treatment of Complicated Skin and Skin‐Structure Infections in Adults: Results of a Prospective, Randomized, Double‐Blind Multicenter Study
2002
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Honokiol: A Novel Natural Agent for Cancer Prevention and Therapy
2012 Standout
Mechanisms for oncogenic activation of the epidermal growth factor receptor
2007
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
2015 Standout
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
A systematic review of the effectiveness of interventions in the management of infection in the diabetic foot
2012
Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis
2009
Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non–Small-Cell Lung Cancer
2005
Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis
2016 Standout
Epidermal Growth Factor Receptor Inhibitors in Development for the Treatment of Non–Small Cell Lung Cancer
2006
Piperacillin–tazobactam: a β-lactam/β-lactamase inhibitor combination
2007
Three Decades of β-Lactamase Inhibitors
2010 Standout
Practical Guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update)
2020 Standout
Aromatic Sulfonyl Fluorides Covalently Kinetically Stabilize Transthyretin to Prevent Amyloidogenesis while Affording a Fluorescent Conjugate
2013 StandoutNobel
Natural product and natural product derived drugs in clinical trials
2014 Standout
2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infectionsa
2012 Standout
Neurotoxicity Caused by the Treatment with Platinum Analogues
2011
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
2006 Standout
A series of systematic reviews to inform a decision analysis for sampling and treating infected diabetic foot ulcers
2006
Arylfluorosulfates Inactivate Intracellular Lipid Binding Protein(s) through Chemoselective SuFEx Reaction with a Binding Site Tyr Residue
2016 StandoutNobel
Lapatinib: Current Status and Future Directions in Breast Cancer
2006
The Essential Medicinal Chemistry of Curcumin
2017 Standout
High throughput glutathione and Nrf2 assays to assess chemical and biological reactivity of cysteine-reactive compounds
2013
Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
2007
Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer
2010
Down-regulation of Integrin α2 Surface Expression by Mutant Epidermal Growth Factor Receptor (EGFRvIII) Induces Aberrant Cell Spreading and Focal Adhesion Formation
2005
Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update)
2020
Works of Irene Eiseman being referenced
Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer
2002
Increased Bioavailability of Intravenous Versus Oral CI-1033, a Pan erbB Tyrosine Kinase Inhibitor: Results of a Phase I Pharmacokinetic Study
2006
Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer
2002
A Phase I Clinical and Pharmacokinetic Study of Oral CI-1033 in Combination with Docetaxel in Patients with Advanced Solid Tumors
2006
Phase I pharmacokinetic (PK) and safety study of intravenous (IV) CI-1033 in patients with advanced solid tumors
2004
Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non–Small-Cell Lung Cancer
2007
Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule
2004
Phase I pharmacokinetic (PK) and safety study of intravenous (IV) CI-1033 in patients with advanced solid tumors
2004
Phase 1 Clinical and Pharmacokinetics Evaluation of Oral CI-1033 in Patients with Refractory Cancer
2005
Phase I Clinical and Pharmacodynamic Evaluation of Oral CI-1033 in Patients with Refractory Cancer
2007
Clinafloxacin versus Piperacillin-Tazobactam in Treatment of Patients with Severe Skin and Soft Tissue Infections
2001